Buradasınız

Anasayfa » Content

Ense Kalınlığı ile Down Sendromu Taraması

SCREENING DOWN SYNDROME WITH NUCHAL TRANSLUCENCY

Journal Name:

  • Türkiye Aile Hekimliği Dergisi

Publication Year:

  • 2004

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
The most frequently used antenatrel test performed is made for screening Down syndrome. The syndrome, described first by Langdon Down in 1866, is the most commonly seen chromosomal abnormality in live births. In 1980s, the syndrome was screened by only maternal age, then the triple test was used. In early 1990s, it was observed that there is increased nuchal thickness in the first trimester ultrasound of fetuses with Down syndrome. After years of research, a first trimester screening test with nuchal thickness as the main parameter is actually under use in many centers worldwide. This review examines this first trimester screening test, based on the com¬bination of fetal nuchal thickness, maternal age and maternal serum biochemistry at 10-14 weeks of gestation.
Bookmark/Search this post with
Abstract (Original Language): 
Gebelikte en sık uygulanan tarama testi Down sendromunu saptamaya yönelik olandır. ilk defa 1866'da Langdon Down'in tanımladığı sendrom, canlı doğumlarda en sık rastlanan kromozom anomalisidir. Down sendromu, 1980'lerde maternal yaş ile saptanmaya çalışılıyordu, daha sonra üçlü test uygulamaya girdi. 1990'ların başında Down sendromlu fetusların 1. trimester ultrasonlarında ense kalınlığının arttığı saptandı. Yıllar süren çalışmalar sonucunda ana parametresi ense kalınlığı (EK) ölçümü olan 1. trimester tarama testi bugün artık bazı merkezlerde klinik uygulamaya girmiştir. Bu derlemede fetal EK, maternal yaş ve maternal serum biyokimyası kullanılarak, gebeliğin 11-14. haftalarında uygulanan 1. trimester tarama testi değerlendirilmektedir
FULL TEXT (PDF): 
PDF icon arastrmx_116859_8_pp_174-176.pdf
  • 4
174-176
  • Turkish

REFERENCES

References: 

1. Wald NJ, Kennard A, Hacksaw AK, McGuire A. Antenatal screening for Down's syndrome. J Med Screen 1997; 4: 181-246.
2. Benacerraf BR, Barrs VA, Laboda LA. A sonographic sign for detection in the second trimester of the fetus with Down's syndrome. Am J Obstet Gynecol 1985; 151: 1078-9
3. Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop-clinic: A review of three years prospective experience. Br J Obstet Gynaecol 2003; 110(3):
281-6
4. Hyett J, Perdu M, Sharland GK, Nicolaides KH. Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: population based cohort study. BMJ 1999; 318: 81-5.
5. Souka AP, Snijders RJM, Novakov A, Nicolaides KH. Defects and syndromes in chromosomally normal fetuses with increased nuchal trans-lucency thickness at 10-14 weeks of gestation. Ultrasound Obstet Gyne-
col 1998; 11: 391-400.
6. Souka AP, Krampl E, Bakalis S, Nicolaides KH. Outcome of preg¬nancy in chromosomally normal fetuses with increased nuchal translu-cency in the first trimester. Ultrasound Obstet Gynecol 2001; 18: 9-17.
7. Braithwaite JM, Kadir RA, Pepera TA, Morris RW, Thompson PJ, Economides DL. Nuchal translucency measurement: training of potenti¬al examiners. Ultrasound Obstet Gynecol 1996; 8: 192-5.
8. Snijders RJM, Noble P, Sebire N, Nicolaides KH. UK multicentre pro¬ject on assessment of risk of trisomy 21 by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Lancet 1998; 351:
343-6.
9. Whitlow BJ, Chatzipapas IK, Economides DL. The effect of fetal neck position on nuchal translucency measurement. Br J Obstet Gynaecol
1998; 105: 872-6
10. Szabo J, Gellen J. Nuchal fluid accumulation in trisomy 21 detected by vaginal sonography in first trimester. Lancet 1990; 336: 1133.
11. Nicolaides KH, Azar G, Byrne D, Mansur C, Marks K. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first tri¬mester of pregnancy. Br Med J 1992; 304: 867-89.
12. Malone FD, Berkowitz RL, Canick JA, D'Alton ME. First trimester screening for aneuploidy: research or standard of care? Am J Obstet
Gynecol 2000; 182: 490-6.
13. Wapner RJ. BUN Study Group. First trimester aneuploid screening: results of the NICHD multicenter study. Am J Obstet Gynecol 2001; 185:
S70.
14. Wald NJ, Hackshaw AK. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome. Prenat Diagn 1998;18: 511-23.
15. Biagiotti R, Cariati E, Brizzi L, D'Agat A. Maternal serum screening for Down syndrome in the first trimester of pregnancy. Br J obstet
Gynaecol 1995; 102: 660-2
16. Spencer K, Noble P, Snijders RJM, Nicolaides KH. A screening prog¬ram for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free B-human chorionic gonodotropin and pregnancy as¬sociated plasma protein-A. Ultrasound Obstet Gynecol 1999; 13: 231-7.
17. Bindra R, Heath V, Liao A, Spencer K, Nicholaides KH. One-stop clin¬ic for assessment of risk of Trisomy 21 at 11-14 weeks: a prospective study of 15,030 pregnancies. Utrasound Obstet Gynecol 2002; 20: 219-25.
18. Cicero S, Curcio P, Papageorghiou A, Nicolaides K. Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: an obser¬vational study. Lancet 2001; 358: 1665-7.
19. Welch KK, Malone FD. Nuchal Translucency-Based Screening. Clin
Obstet and Gynecol 2003; 46(4): 909-22.
20. Nicolaides KH, Snijders RJM, Gosden CM, Berry C, Campbell S.
Ultrasonographically detectable markers of fetal chromosomal abnor¬malities. Lancet 1992; 340: 704-7.
21. Nyberg DA, Luthy DA, Resta RG, Nyberg BC, Williams BA. Age-ad¬justed ultrasound risk assessment for fetal Down's Syndrome during the second trimester: Description of the method and analysis of 142 cases.
Ultrasound Obstet Gynecol 1998; 12: 8-14.

Thank you for copying data from http://www.arastirmax.com